In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Pfizer (PFE) announced in a press release today that the European Commission has approved Trazimera for HER2 overexpressing breast cancer and HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma.
For 3Q17, Merck surpassed Wall Street analysts’ estimates for EPS but missed the revenue estimate. It reported EPS of $1.11 on revenues of $10.3 billion.
Mylan’s (MYL) Rest of the World segment includes revenues from third-party sales of generics products and specialty segment products reported from countries including New Zealand, India, Japan, and Australia as well as emerging markets including Asia, Brazil, Africa, and the Middle East.
Gilead’s Harvoni Harvoni is one of Gilead Sciences’ (GILD) largest-selling drugs. A combination of Ledipasvir and Sofosbuvir, it is approved for the treatment of hepatitis C infections. Harvoni’s importance The above chart shows Harvoni revenue over the last few quarters. During 3Q17, Harvoni contributed ~15% of Gilead’s revenue, and in 2Q17, it contributed ~21%. Harvoni […]
Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.
Segment-wise performance Johnson & Johnson (JNJ) reported 2.9% growth in operating revenue between 2Q16 and 2Q17. However, the company missed analysts’ 2Q17 estimate and reported revenue of $18.8 billion due to a 1% foreign exchange impact. Analysts had forecast revenue of $19 billion. Johnson & Johnson’s business is broken down into the pharmaceuticals segment, consumer […]
Pfizer (PFE) is set to release its 2Q17 earnings on August 1, 2017. Analysts estimate earnings per share of $0.66 on revenues of ~$13.1 billion for 2Q17.
Eli Lilly and Company (LLY) released its 2Q17 earnings on July 25, 2017, reporting an 8.0% rise in its top line to $5.8 billion for 2Q17 compared to 2Q16.
Pharmaceutical segment Johnson & Johnson’s (JNJ) pharmaceutical segment comprises its immunology, infectious disease, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension franchises. Immunology franchise The major blockbuster drugs under the immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The immunology franchise reported revenue of $3 billion in 2Q17, including an operational decrease of ~1.9% and a […]
Johnson & Johnson’s (JNJ) Consumer Healthcare segment includes the baby care, oral care, skincare, over-the-counter products, women’s health, and wound care franchises.
Merck & Co.’s (MRK) Anacetrapib is an investigational drug developed for the treatment of hypercholesterolemia. The drug also reduces the risk of cardiovascular disease.
Pfizer (PFE) has started a Phase 1 clinical trial to evaluate an investigational vaccine for protection against Group B streptococcus in infants younger than three months.
Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017.
The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.
The US pharmaceutical sector is made up of different areas geared toward the development, production, and marketing of drugs. Let’s take a look at some of the sector’s 1Q17 mergers and acquisitions.
Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug, Eliquis. The segment contributed nearly 18.0% to the company’s total revenues in 4Q16.
Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.
Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.
Products with declining revenues So far, we’ve discussed growth trends and positive growth products for Pfizer (PFE). Let’s now discuss the products that hampered growth. The overall share of revenues for the Essential Health business increased to 46% of total revenues in 2Q16 from 44% of total revenues in 2Q15, driven by revenue growth from […]
Pfizer-Anacor deal On June 23, 2016, Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC). The stock transaction is valued at $99.25 per Anacor share, resulting in a total enterprise value of ~$5.2 billion. What is Anacor? Anacor is a California-based biopharmaceutical company. It is focused on developing and commercializing boron-based drugs for the treatment […]
Pfizer-Medivation deal On September 27, 2016, Pfizer (PFE) completed the acquisition of Medivation (MDVN). The stock transaction is valued at $81.50 per Medivation share, resulting in a total enterprise value of ~$14 billion. What is Medivation? Medivation is a California-based biopharmaceutical company. It is focused on developing and commercializing innovative therapies for the treatment of […]
On August 24, Pfizer (PFE) announced its acquisition of AstraZeneca’s (AZN) small-molecule anti-infective portfolio, which is primarily outside the United States.
Vyxeos would offer commercial synergies to the Jazz Pharmaceuticals portfolio in the form of a complementary targeted prescriber base of AML patients who undergo HSCT.
Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC) on June 23, 2016. The acquisition will strengthen Pfizer’s portfolio of inflammatory disease products.
The European Medicines Agency’s CHMP (Committee for Medicinal Products for Human Use) recommended the suspension of Alkem’s Riluzole Alkem on June 24, 2016.
Some of the challenges the pharmaceutical industry faces include R&D failures, changes in regulatory procedures, litigation, patent expiries, and foreign currency movements.
The Checkmate-205 study is the phase II study that compares safety and efficacy of Opdivo in the treatment of patients with relapsed or refractory classical Hodgkin lymphoma
JNJ has surpassed all estimates for EPS in the past, and analysts estimate that JNJ will generate an EPS of $1.65 on revenues of ~$17.5 billion in 1Q16.
One of the most prominent effects of technology is on the asset side of the balance sheet. Many technologies drive companies to employ fewer assets in order to generate higher returns.
On November 30, 2015, Bristol-Myers Squibb (BMY) and AbbVie (ABBV) announced that the FDA has approved Empliciti for treatment of patients with multiple myeloma.
The FDA has now approved Opdivo for the treatment of advanced RCC (renal cell carcinoma) based on the results of a phase 3 study called CheckMate -025.
